Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Improving the Outcome of High-risk Aggressive B-cell Lymphoma Patients With Nivolumab Maintenance Therapy. The NivoM Trial

NCT03569696 is registered in ClinicalTrials.gov with Meirav Kedmi MD as lead sponsor.

NCT NCT03569696
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03569696 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Improving the Outcome of High-risk Aggressive B-cell Lymphoma Patients With Nivolumab Maintenance Therapy. The NivoM Trial
Lead sponsor
Meirav Kedmi MD
Phase
Phase 2
Overall status
Unknown status
Start date
October 8, 2018
Completion date
September 30, 2023
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, b-cell